• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Pharm Biopharm . Pronounced therapeutic potential of oligonucleotides fixed on inorganic nanoparticles against highly pathogenic H5N1 influenz

tetano

Editor, Senior Moderator
Eur J Pharm Biopharm


. 2021 Mar 19;S0939-6411(21)00072-2.
doi: 10.1016/j.ejpb.2021.03.006. Online ahead of print.
Pronounced therapeutic potential of oligonucleotides fixed on inorganic nanoparticles against highly pathogenic H5N1 influenza A virus in vivo


Asya Levina[SUP] 1 [/SUP], Marina Repkova[SUP] 1 [/SUP], Nadezhda Shikina[SUP] 2 [/SUP], Zinfer Ismagilov[SUP] 2 [/SUP], Maxim Kupryushkin[SUP] 1 [/SUP], Anna Pavlova[SUP] 1 [/SUP], Natalia Mazurkova[SUP] 3 [/SUP], Dmitrii Pyshnyi[SUP] 1 [/SUP], Valentina Zarytova[SUP] 4 [/SUP]



Affiliations

Abstract

This study describes the effective attack of oligonucleotides on the viral genome of highly pathogenic H5N1 influenza A virus (IAV) in vivo using for the first time the new delivery system consisting of biocompatible low-toxic titanium dioxide nanoparticles and immobilized polylysine-containing oligonucleotides with the native (ODN) and partially modified (ODN[SUB]m[/SUB]) internucleotide bonds. Intraperitoneal injection of the TiO[SUB]2[/SUB]?PL-ODN nanocomposite provided 65-70% survival of mice, while intraperitoneal or oral administration of TiO[SUB]2[/SUB]?PL-ODN[SUB]m[/SUB] was somewhat more efficient (?80% survival). The virus titer in the lung was reduced by two-three orders of magnitude. The nanocomposites are nontoxic to mice under the used conditions. TiO[SUB]2[/SUB] nanoparticles, unbound ODN, and the nanocomposite bearing the random oligonucleotide showed an insignificant protective effect, which indicates the ability of targeted oligonucleotides delivered in mice in the nanocomposites to site-specifically interact with complementary RNAs. The protection of oligonucleotides in nanocomposites by TiO[SUB]2[/SUB] nanoparticles and partial modification of the internucleotide bonds provides a continued presence of oligonucleotides in the body for the effective and specific action on the viral RNA. The proposed oligonucleotide delivery system can claim not only to effectively inhibit IAV genes but also to turn off other genes responsible for diseases caused by nucleic acids.

Keywords: Influenza A virus; TiO(2)-based nanocomposites; mice; oligonucleotides; virus titer.
 
Back
Top Bottom